# EDIT — slm-full-gpu

## Metadata

ticker: EDIT
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: ef4dddfdc1d967d7192dafcd8eca9b94ec66cce8091971f7133f28f4640d506a
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 650, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 22.262, "latency_s_total": 22.262, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 495, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 15.7, "latency_s_total": 15.7, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 126, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 10.632, "latency_s_total": 10.632, "parse_failure": 0, "prompt_tokens": 650, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 160, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 13.24, "latency_s_total": 13.24, "parse_failure": 0, "prompt_tokens": 644, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 215, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 17.487, "latency_s_total": 17.487, "parse_failure": 0, "prompt_tokens": 567, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 154, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 14.662, "latency_s_total": 14.662, "parse_failure": 0, "prompt_tokens": 730, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 955, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 19.442, "latency_s_total": 19.442, "parse_failure": 0, "prompt_tokens": 1688, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.75,
  "currency": "USD",
  "market_cap": 422345088.0,
  "forward_pe": -3.651428,
  "week_52_high": 4.33,
  "week_52_low": 1.66,
  "financial_currency": "USD",
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin_pct": -157.32,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the company's filings, here are the key takeaways regarding its financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stands at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to sustain operations. If it cannot raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate research, product development, or commercialization efforts.
*   **Cash Runway:** Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027.
*   **Limited External Funding Sources:** The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments and other amounts under a license agreement with Vertex.
*   **Future Financing:** Until the company can generate substantial product revenues, it expects to finance cash needs through public or private equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. Raising additional capital may cause dilution to stockholders or require relinquishing rights to technologies.

**Operational Status and Development**
*   **Preclinical Stage:** The company is currently only in the preclinical testing stages for its most advanced research programs, including EDIT-401.
*   **Long Timeline to Commercialization:** It is expected to be many years, if ever, before a product candidate is ready for commercialization. The company does not expect to have commercially available medicines for years, if at all.
*   **Increasing Expenses:** Expenses are expected to increase significantly as the company continues preclinical studies, initiates clinical trials for EDIT-401 and other candidates, seeks marketing approvals, and potentially establishes sales, marketing, and manufacturing infrastructure.

**Profitability and Risks**
*   **Uncertainty of Profitability:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis.
*   **Impact of Failure to Profit:** Failure to become and remain profitable could decrease the company's value, impair its ability to raise capital, and potentially cause stockholders to lose all or part of their investments.
*   **Regulatory and Economic Risks:** Expenses could exceed expectations if regulatory authorities (such as the FDA or EMA) require additional studies. Additionally, unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Substantial Funding:** The company requires substantial additional funding to support ongoing activities, including the preclinical and clinical development of product candidates like EDIT-401. If capital cannot be raised when needed, the company may be forced to delay, reduce, or eliminate research, product development, or commercialization efforts. Existing cash and equivalents are expected to fund operations only through the third quarter of 2027.
*   **Regulatory and Development Risks:** The company is currently in the preclinical testing stages for its most advanced research programs. Expenses could increase beyond expectations if regulatory authorities require additional studies. There is no guarantee that product candidates will receive marketing approval or achieve commercial success.
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or hindering the ability to raise capital on acceptable terms.
*   **Commercialization Risks:** Even if products are approved, the company may not become profitable. Commercialization will require significant expenses for sales, marketing, manufacturing, and distribution, and revenues are not expected for many years, if at all.
*   **Intellectual Property and Collaboration Dependencies:** The company relies on collaborations and license agreements (such as those with Bristol Myers Squibb and Vertex Pharmaceuticals) for funding and technology. Future capital requirements depend on factors such as the success of these collaborations, the costs of maintaining intellectual property, and the ability to secure healthcare coverage and reimbursement for approved products.
*   **Dilution and Operational Restrictions:** Raising additional capital through equity offerings may cause dilution to stockholders, restrict operations, or require the company to relinquish rights to its technologies or product candidates.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.75 with a market capitalization of approximately $422.3 million. The company reported revenue of $47.0 million but faces significant profitability challenges, evidenced by a net loss of $73.9 million and a negative profit margin of -157.32%. Consequently, the forward P/E ratio is negative, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk investment profile typical of early-stage biotechnology firms reliant on future pipeline developments rather than current cash flow.

### Recent Developments

Editas Medicine, Inc. (EDIT) continues to navigate significant financial headwinds, reporting a net loss of $73.9 million and a negative profit margin of -157.32%, underscoring the company's reliance on external capital to sustain operations. The stock currently trades near the lower end of its 52-week range at $2.75, reflecting investor caution amid ongoing clinical and commercialization risks. While recent SEC filings highlight standard forward-looking statement disclaimers, the absence of specific breakthrough news suggests a period of consolidation rather than immediate catalyst-driven growth. Investors should monitor upcoming cash burn rates and pipeline milestones closely, as the company remains in a high-risk, pre-profitability phase typical of early-stage biotechnology firms.

### SEC Filing Highlights
Editas Medicine reported net losses of $160.1 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it remains in the preclinical stage with no commercialized products. The company’s existing cash runway is projected to sustain operations only through the third quarter of 2027, necessitating substantial additional capital to fund ongoing research and development. Primary future funding relies on contingent payments from collaboration agreements with BMS and Vertex, alongside potential equity or debt financings that may cause significant shareholder dilution. Management warns that the company expects to incur losses for the foreseeable future and may never achieve sustainable profitability, posing a risk of total investment loss.

### Risk Factors

*   **Substantial Capital Requirements and Dilution Risk:** The company has a history of significant operating losses and an accumulated deficit of $1.6 billion, with existing cash expected to fund operations only through Q3 2027. Failure to secure additional funding could force a reduction in development efforts, while raising capital via equity offerings may result in significant shareholder dilution and operational restrictions.
*   **Early-Stage Development and Regulatory Uncertainty:** Most advanced programs, such as EDIT-401, remain in preclinical testing with no guarantee of regulatory approval or commercial success. Expenses may exceed expectations if additional studies are required, and the company may never achieve profitability even if products are eventually approved.
*   **Dependency on Collaborations and External Factors:** The company relies heavily on license agreements and collaborations (e.g., with Bristol Myers Squibb and Vertex Pharmaceuticals) for technology and funding. Business operations are also vulnerable to unfavorable economic conditions, political unrest, and supply chain disruptions that could hinder capital raising or commercialization efforts.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine, Inc. is a preclinical-stage biotechnology firm focused on CRISPR-based therapies, currently navigating a precarious financial position marked by a $1.6 billion accumulated deficit and a cash runway extending only through the third quarter of 2027. The stock’s current valuation reflects significant investor caution regarding the company’s ability to sustain operations without substantial external capital or successful milestone payments from collaborations with partners like BMS and Vertex. The single most important near-term variable shaping the investment outcome is the company’s success in securing additional funding or triggering contingent payments to bridge the gap to its projected liquidity exhaustion.

### Outlook
The directional outlook for Editas Medicine is cautiously cautious, characterized by a high-stakes dependency on capital preservation and partnership execution rather than organic growth. Key variables to monitor include the timing and magnitude of contingent payments from BMS and Vertex, which serve as critical lifelines for extending the cash runway, as well as the company’s ability to manage dilution if equity financing becomes necessary. The investment thesis would be strengthened by clear evidence of sustained collaboration revenue or successful progression of preclinical assets that de-risks the pipeline; conversely, the view would weaken significantly if the company faces delays in securing necessary funding or encounters setbacks in its research programs that accelerate cash burn beyond current projections.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "a $1.6 billion accumulated deficit"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state "As of December 31, 2025, the accumulated deficit stands at $1.6 billion," and the pre-written SEC Filing Highlights section repeats this figure.

---

CLAIM: "a cash runway extending only through the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027," confirmed in both RAG sections and the pre-written SEC Filing Highlights.

---

CLAIM: "collaborations with partners like BMS and Vertex"
LABEL: SUPPORTED
REASON: Both RAG sections and the pre-written Risk Factors section explicitly name Bristol Myers Squibb (BMS) and Vertex Pharmaceuticals as collaboration/license partners providing contingent payments.

---

**OUTLOOK**

---

CLAIM: "contingent payments from BMS and Vertex"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments and other amounts under a license agreement with Vertex," and this is echoed in the pre-written sections.

---

CLAIM: "extending the cash runway" [beyond Q3 2027, implied by context]
LABEL: INFERENCE
REASON: The cash runway endpoint of Q3 2027 is explicitly stated in the source data, and the claim that contingent payments could extend it beyond that point is a direct logical derivation from the stated facts about funding needs and the role of those payments.

---

CLAIM: "successful progression of preclinical assets" [as a pipeline de-risking milestone]
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and pre-written Risk Factors explicitly state that the company's most advanced programs, including EDIT-401, remain in preclinical testing, confirming the characterization of assets as preclinical-stage.

---

**ADDITIONAL CHECKS — Claims present in the Executive Summary that are qualitative but carry implicit quantitative or factual grounding:**

---

CLAIM: "preclinical-stage biotechnology firm"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "The company is currently only in the preclinical testing stages for its most advanced research programs, including EDIT-401."

---

CLAIM: "the company's ability to sustain operations without substantial external capital"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state the company "requires substantial additional capital to sustain operations" and may be forced to delay or eliminate efforts if capital cannot be raised.

---

**SUMMARY OF FINDINGS:**
All specific quantitative claims in the Executive Summary and Outlook sections — the $1.6 billion accumulated deficit, the Q3 2027 cash runway, the named partners BMS and Vertex, and the preclinical characterization of assets — are directly supported by the source data. No figures in these sections are unsupported or fail any of the arithmetic, period-label, or presence checks. One forward-looking directional claim (cash runway extension) is appropriately labeled as an inference derivable from stated facts.
